Kornimate/medical-research-clean huggingface dataset:
long-term safety of dasatinib in patients with chronic myelogenous leukemia or philadelphia chromosome positive acute lymphoblastic leukemia

Conditions: Leukemia

Summary: this study assesses the long-term safety and tolerability of dasatinib administered to patients with chronic myelogenous leukemia or philadelphia chromosome positive acute lymphoblastic leukemia and experienced clinical benefit from treatment with dasatinib or imatinib in previous protocols.


Eligibility criteria:
key inclusion criteria * signed written informed consent * received treatment in protocols ca180-005, ca180-006, ca180-013, ca180-015 or ca180-017, or ca180-039 * received clinical benefit with dasatinib or imatinib (study ca180017) in the opinion of the investigator * men and women, ages 18 and older key exclusion criteria * a serious uncontrolled medical disorder or active infection that would impair the ability of the patient to receive protocol therapy * dementia or altered mental status that would prohibit the understanding or rendering of informed consent * patients currently taking drugs, including but not limited to quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, erythromycins, clarithromycin, chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, ziprasidone, cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, and lidoflazine, which are generally accepted to have a risk of causing torsades de pointes * patients taking medications known to be potent cyp3a4 inhibitors (ketoconazole, ritonavir) or inducers (rifampin, efavirenz)
anterior cruciate ligament (acl) reconstruction- bioabsorbable screw

Conditions: Rupture of Anterior Cruciate Ligament

Summary: to evaluate the knee functionality, screw integrity, graft integrity, cartilage effect, and bony ingrowth in patients treated with the calaxo screw and milagro screw two years after acl reconstruction.

this study will combine the use of survey response, mri, and x-rays of the knees in dr. spindler's acl reconstructed patients in order to examine long term healing of two types of bioabsorbable screw. we will use a 2-4 yr time point to look at patient reported symptoms of pain and swelling from the surveys and use the x-rays and mris to look at absorption of the screw, healing of the graft, and body reactions to the screw.

Eligibility criteria:
inclusion criteria: * age range: 12-35 years of age at the time of follow-up. * gender: both. * minorities: all. * involved in sports at the time of injury. * participants must be at least two years past the date of acl reconstruction surgery and not more than four years past the date of surgery * bioabsorbable screws used during acl reconstruction surgery exclusion criteria: * age: \ 35 years of age * non-active or unable to participate for health reasons * simultaneous bilateral acl reconstruction surgeries. * if any of the following conditions exist in the ipsilateral knee: * revision acl reconstruction * complex knee injury * if any of the following conditions exist in the contralateral knee: * acl deficient * prior acl reconstruction * prior surgery of any type * insufficient initial documentation * cannot be contacted by phone * neither calaxo nor milagro screw used at the time of acl reconstruction

Keywords: bioabsorbable screw acl reconstruction
a study of agn-195263 for the treatment of meibomian gland dysfunction

Conditions: Meibomian Gland Dysfunction

Summary: this study will evaluate the safety and efficacy of agn-195263 compared to vehicle in patients with meibomian gland dysfunction (mgd) in the eyelids.


Eligibility criteria:
inclusion criteria: * meibomian gland dysfunction in both eyes * best-corrected visual acuity of 20/40 or better in each eye exclusion criteria: * known or suspected prostate cancer * history of breast cancer * using latisse® or any other eye lash growth-stimulating product at least 30 days prior to the screening visit, or anticipated use during the study * contact lens wear in either eye during any portion of the study * unable to instill eye drops correctly * history of corneal refractive surgery in either eye within 1 year
pregnancy & neonatal follow-up of ongoing pregnancies established during clinical trial 38826 (study 38827)(p06056)(completed)

Conditions: Pregnancy; Neonates

Summary: the objective of this trial was to evaluate whether org 36286 treatment for the induction of multifollicular growth in women undergoing controlled ovarian stimulation (cos) for in vitro fertilization (ivf) or intracytoplasmatic sperm injection (icsi) is safe for pregnant subjects and their offspring.

this was an open, prospective follow-up trial to monitor pregnancy, delivery, and neonatal outcome of women who became pregnant during trial 38826. for this trial, no study specific assessments were required, but information obtained in standard practice was used.

Eligibility criteria:
inclusion criteria: * subjects who participated in trial 38826 and became pregnant (as confirmed by uss at or beyond 10 weeks after et) after having received at least one dose of either org 36286 or puregon®; and * able and willing to give written informed consent. exclusion criteria: * none

Keywords: neonatal outcome congenital malformations in-vitro fertilization controlled ovarian stimulation follow-up
effects of dairy- and berry-based snacks on nutritional and functional status and quality of life in older people

Conditions: Nutrition Disorders in Old Age

Summary: malnutrition or its risk is common among older people, especially among those receiving home care services. it impairs the quality of life of the older people and results in significant costs to society. to maintain adequate nutrition, increased meal frequency is important. in addition to main meals, regular consumption of tasty, convenient, nutrient- and energy-dense snacks is recommended. the purpose of this study is to investigate the effects of dairy- and berry-based snack consumption on nutritional and functional status and quality of life among vulnerable older people at home care.


Eligibility criteria:
inclusion criteria: * home care clients of the city of kuopio exclusion criteria: * advanced dementia

Keywords: older people nutrition snack dairy protein berries
the use of gastrografin in chronic radiation enteropathy with small bowel obstruction

Conditions: CRE-induced SBO

Summary: chronic radiation enteropathy (cre) is a major issue for long-term cancer survivors. the aim of this study was to clarify the diagnostic and therapeutic effect of the gastrografin (gg) challenge for patients with cre induced small bowel obstruction sbo.


Eligibility criteria:
inclusion criteria: * with a first diagnosis of cre combined with sbo and asbo that was determined by clinical history, computed tomography (ct) manifestation, and conﬁrmed by intraoperative and histologic ﬁndings. * radiation therapy completed at least 6 months before enrolment. exclusion criteria: * a colostomy or ileostomy; * large bowel obstruction; * with a known history of either allergy or hypersensitivity to iodinated contrast agents; * with signs of strangulation; * metastatic disease; * obstruction within 4 weeks after a recent operation or serious comorbidity.
graded motor imagery training in shoulder impingement syndrome

Conditions: Shoulder Impingement Syndrome; Pain

Summary: the aim of this study is to investigate the effects of graded motor imagery (gmi) training on pain, functionality, disability and daily living activities in patients diagnosed with shoulder impingement syndrome.

in this study 42 voluntary patients with shoulder impingement syndrome, aged between 25-65 years will be randomly divided into two groups; group1: "gmi + conventional physiotherapy", group 2: "conventional physiotherapy". all participants will receive treatment with a physiotherapist three times a week for six-weeks (18 sessions). at the end of the 6th week, it will be followed regularly with a six-week home exercise program. it will be evaluated by a physiotherapist three times in total (before treatment, at the end of six-weeks of treatment and after six-weeks of follow-up). in addition, all patients will undergo an interim evaluation in terms of primary outcome measures (vas and dash score) at week three. the shoulder pain on activity, at rest and at night will be assessed with visual analog scale (vas), joint range of motion (rom) will be measured with digital goniometer, strength of shoulder flexor, abductor, external and internal rotator muscles will be assessed with digital dynamometer, functional status will be evaluated with disabilities of the arm, shoulder and hand (dash) questionnaire, functional status of the hand will be evaluated with jebsen-taylor hand function test (jthft), lateralization evaluation will be assessed with the recognise™ application (shoulder and hand), and motor imagery will be evaluated with the kinesthetic and visual imagery questionnair (kviq). patient satisfaction will be evaluated by the global rating of change scale.

Eligibility criteria:
inclusion criteria: * aged between 25-65 years old, * having been diagnosed with shoulder impingement syndrome by physical examination and mri as a result of shoulder pain lasting at least 3 months, * presence of a painful arc between 60° and 120° in shoulder flexion / abduction (elevation) movements, * the standardized mini mental test result must be at least 24 points, * not having seen imagery practice before, exclusion criteria: * having severe mental and communication problems, * having undergone surgical treatment on the same upper extremity, * presence of acute trauma, peripheral nervous system lesion, fracture or complete tendon rupture in the affected shoulder, * presence of other pathologies such as adhesive capsulitis of the shoulder joint complex and glenohumeral instability, * presence of radiotherapy history on the same side as the affected shoulder, * presence of congenital deformity, * symptomatic cervical spine pathology, * presence of other neurological or rheumatological disorders affecting upper motor function, * having any chronic disease that would prevent participation in the treatment program, * having attended a physiotherapy program within the last month.

Keywords: shoulder impingement syndrome mirror neurons pain functional status rehabilitation
sacubitril/valsartan versus valsartan for hypertensive patients with acute myocardial infarction

Conditions: Myocardial Infarction; Hypertension

Summary: studies have demonstrated that the early initiation of acei/arb to patients with acute myocardial infarction is beneficial, especially in patients combined with reduced lvef or mild-moderate heart failure. therefore, acei/arb is a traditional treatment for patients post-infarction. recent clinical trials have demonstrated that sacubitril/valsartan is more beneficial than ramipril to patients post-pci.besides, sacubitril/valsartan is also effective for essential hypertension.this study aims to assess the effect of sacubitril/valsartan on short-term prognosis in hypertensive patients with acute myocardial infarction compared against valsartan.


Eligibility criteria:
inclusion criteria: 1. diagnosed with new-onset mi, either stemi or nstemi, according to the fourth universal definition of mi (thygesen et al. 2019), disease onset within 7 days. 2. patients are previously diagnosed with essential hypertension or newly diagnosed with essential hypertension. 3. capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and the protocol. exclusion criteria: 1. patients with severe renal dysfunction. (gfr\<60mmol/l). 2. patients who have recently undergone immunosuppressive therapy. 3. patients who are known to be allergic to sacubitril/valsartan and valsartan. 4. patients who are hemodynamically unstable. 5. chronic symptomatic heart failure within the last year and known reduced ejection fraction (lvef≤40 %). 6. severe hepatic impairment (child-pugh class c) at the time of inclusion into the trial. 7. any non-cv condition, such as active malignancy requiring treatment at the time of screening, or severe diseases with a life expectancy of fewer than two years based on the investigator´s clinical judgment. 8. currently on treatment with sacubitril/valsartan or an acei/arb.

Keywords: sacubitril/valsartan valsartan myocardial infarction hypertension
characterization of biophysical and mechanical parameters on skin of breast cancer patients

Conditions: Breast Cancer; Estrogen Receptor Positive Tumor

Summary: aim of this study is to characterize the chemical/physical and structural parameters of the skin in patients with breast cancer undergoing oncological adjuvant treatment in order to understand how to prevent and manage adverse skin events during hormone therapy, also through the formulation of new functional dermocosmetics.

breast cancer is the most frequent neoplasm in women in industrialized countries. after surgery, an adjuvant systemic treatment is generally proposed (hormone therapy, chemotherapy, molecular targeted therapy). side effects of endocrine treatments, including skin toxicities, are frequent and often underestimated, leading to poor treatment adherence that can compromise therapeutic outcomes. among adjuvant chemotherapy treatments, one of the most used drug is paclitaxel: at skin level it can induce rash, dry skin and itching. the combination of radiotherapy with these oncological treatments could aggravate cutaneous side effects. aim of this study is to characterize the chemical/physical and structural parameters of the skin in patints with breast cancer undergoing adjuvant treatment, performing specific skin tests with professional instruments and adequate personnel. the evaluation will be carried out in estrogen receptor (er) positive breast cancer patients undergoing adjuvant therapy with tamoxifen or aromatase inhibitor or paclitaxel +/- adjuvant radiotherapy.

Eligibility criteria:
inclusion criteria: * age between 40 and 70 years * subjects who are receiving treatment with tamoxifen, aromatase inhibitor or paclitaxel in adjuvant therapy +/- adjuvant radiotherapy * subjects who are receiving hormonal therapy must have suspended any chemotherapy for at least 30 days exclusion criteria: * presence of known chronic skin pathologies before adjuvant treatment start (psoriasis, lupus, atopic dermatitis) * inability to understand and will * unavailability to carry out all the tests required by the protocol

Keywords: estrogen receptor positive breast cancer adjuvant treatment skin toxicity
evaluation of endometrial stromal cell apoptosis in adenomyosis

Conditions: Endometriosis

Summary: our previous results revealed that the expression of killer inhibitory receptors (kirs) on nk cells was decreased in eutopic endometrium in women with adenomyosis. it implies that the formation of adenomyosis might be due to abnormal endometrial tissues, but not the aberrant local immunological dysfunction in myometrium. in addition, in vitro coculture of macrophages and endometrial stromal cells (esc) increase the expression of il-6 mrna in esc, which might further enhance the proliferation of esc and subsequently result in the formation of ectopic endometrial implants in adenomyosis. besides, another possible mechanism is the abnormal apoptosis of esc in adenomyosis. in endometriosis, apoptotic endometrial cells were found to be decreased, which possibly accounts for the formation of endometriosis. however, there have not been reports investigating the apoptosis of esc in adenomyosis. in this study, we try to investigate apoptotic esc with flow cytometry in women with and without adenomyosis. annexin v, bcl-2, and caspase-3 were measured to represent the degree of apoptosis in esc.

eutopic endometrium was obtained and separated into single endometrial stromal cell (esc) in women with adenomyosis (study group) and without adenomyosis (control group). annexin v-pe, bcl-2-pe, and caspase-3-pe are stained, and flow cytometry is done to measure the degree of apoptosis in esc. on the other hand, another half of esc are cultured for 24h, and also annexin v-pe, bcl-2-pe, and caspase-3-pe are stained, and flow cytometry is done.

Eligibility criteria:
inclusion criteria: * women with adenomyosis * at early- to mid-secretory phases exclusion criteria: * postmenopausal * malignancy

Keywords: adenomyosis apoptosis flowcytometry
branch retinal vein occlusion (brvo) treatment with bevacizumab and dexamethasone or bevacizumab only.

Conditions: Branch Retinal Vein Occlusion

Summary: the aim of this study is to evaluate the visual outcome and prognostic factors after intraocular injections of bevacizumab or combination of bevacizumab and dexamethasone under pro re nata treatment regimen for branch retinal vein occlusion (brvo) patients.

the aim of this study is to evaluate the clinical outcome after intraocular injections of bevacizumab or combination of bevacizumab and dexamethasone under pro re nata treatment regimen for the patients with branch retinal vein occlusion (brvo) patients. mean change of logarithm of the minimal angle of resolution (logmar) visual acuity (va), central foveal thickness (cft), contrast sensitivity (cs) as well as predictive factors including best-corrected visual acuity (bcva), vision related questionnaires and various other ocular parameters will be assessed.

Eligibility criteria:
inclusion criteria: 1. written informed consent must be obtained before any study assessment is performed 2. diagnosis of visual impairment exclusively due to me secondary to brvo 3. bcva score at screening and baseline between 10/40 (0.5) to 20/400 (0.05) on the snellen chart. 4. central foveal thickness (cft) ≥ 300 µm 5. naive eyes exclusion criteria: 1. pregnant or nursing (lactating) women 2. stroke or myocardial infarction less than 3 months before screening 3. uncontrolled blood pressure defined as systolic value of \>160 mm hg or diastolic value of \>100 mm hg at screening or baseline. 4. any active periocular or ocular infection or inflammation at screening or baseline in either eye 5. uncontrolled glaucoma at screening or baseline or diagnosed within 6 months before baseline in either eye 6. neovascularization of the iris or neovascular glaucoma in the study eye 7. use of any systemic or ocular antivascular endothelial growth factor (anti-vegf) drugs within 6 months before baseline 8. panretinal laser photocoagulation performed, anticipated or scheduled in the study eye 9. focal or grid laser photocoagulation in the study eye 10. use of intra- or periocular corticosteroids (including sub-tenon) or ocular anti-vegf treatment within 3 months before screening in the study eye 11. any use of intraocular corticosteroid implants (eg, dexamethasone \[ozurdex®\], fluocinolone acetonide \[iluvien®\]) in the study eye
effects of painful compared to painless manual therapy on pain processing in university students with neck pain

Conditions: Neck Pain

Summary: the purpose of this study is to evaluate the effects of provoking pain with manual therapy on pain processing in university students with recurrent or chronic neck pain.

the mechanical stimulus produced in manual therapy (mt) techniques elicits neurophysiological responses within the peripheral and central nervous system responsible for pain inhibition. almost all types of mt elicit a neurophysiological response that is associated with the descending pain modulation circuit. but it has not been demonstrated whether this inhibition occurs through a conditioned pain modulation mechanism generated by the pain that manual therapy techniques may elicit in the patient.

Eligibility criteria:
inclusion criteria: * university students * chronic neck pain (persistent pain \> 3 months almost every day of the week) or recurrent neck pain (repeated episodes of neck pain starting \> 3 months ago with pain-free periods) * non-specific neck pain (pain in the neck region that is not attributable to a known specific such as herniated disc, myelopathy, fractures, spinal stenosis, neoplasm etc. nor is it associated with traumatic causes such as whiplash) * mean nrs score the last week \> 2/10 and presence of pain on the day of assesment and treatment exclusion criteria: * signs of radiculopathy or neuropathic pain * neck surgeries * inflammatory rheumatic * neurological, cardiorespiratory, oncological or psychiatric disease * pregnancy * not being able to read spanish in order to fill in the questionnaires

Keywords: manual therapy physiotherapy physical therapy conditioned pain modulation neck pain
prevalence of inflammatory bowel disease in patients with perianal disease

Conditions: Inflammatory Bowel Disease; Perianal Fistula; Perianal Abscess

Summary: to show that prevalence of inflammation of the small bowel in patients with anorectal disease is under-diagnosed based on colonoscopy ileoscopy alone.

ibd of the small bowel is associated with perianal disease such as ano-rectal abscesses and fistulas. colonoscopy with ileoscopy and small bowel series are relied upon to document the presence of crohn's disease of the small bowel. we suspect that the prevalence of inflammatory small bowel disease is underestimated. in my practice i have cases that had negative colonoscopy ileoscopy and positive findings at capsule endoscopy. these patients are receiving therapy for crohn's disease. it is important to prove that the prevalence is higher. capsule endoscopy (ce) is the "first line tool" diagnostic procedure for the examination of the small bowel. it is performed today in more than 2,900 gi clinics in hospitals, outpatient departments and physicians' offices all over the world using the pillcam® platform. over 500,000 ce procedures with the given pillcam sb have been completed to date.

Eligibility criteria:
inclusion criteria: * patients between the ages of 10 - 80 * patients with anorectal abscess of anorectal fistula * patient is male or female * within three months prior to enrollment, patient has normal test results for at least one of the following tests: 1. colonoscopy with ileoscopy, and/or 2. colonoscopy with small bowel series, and/or 3. colonoscopy with ct enterography * within three months prior to enrollment patient has the following lab tests: blood count, sedimentation rate, crp. ibd serology is optional. * sign informed consent exclusion criteria: * can not sign informed consent * contraindications to colonoscopy ileoscopy or capsule endoscopy * history of established ibd

Keywords: inflammation of the small bowel